◼ Archived
Business
Eli Lilly CFO On Acquisition Spree: 'We Are Taking Bets' On Future Revenue
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly
62 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Eli Lilly stock reaches an all-time high amid surging GLP-1 sales and a heightened price target.
◼ Archived
Business
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
Eli Lilly reports that its new drug, retatrutide, achieved more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
◼ Archived
Business
Mo. Attorney General sends prescription manufacturer Eli Lilly cease-and-desist over drug price policy
Missouri's Attorney General issues a cease-and-desist letter to drug manufacturer Eli Lilly over a contested pricing policy.
◼ Archived
Business
Boeing Stock Plunges After Earnings. 737 Progress Is Not Fast Enough.
Boeing stock craters after earnings reveal slower 737 production progress, production challenges, and cautious growth forecasts.
◼ Archived
Business
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
A US judge has ruled against Novo Nordisk, allowing Eli Lilly to continue running advertisements for its weight-loss medications.
◼ Archived
Health
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Novo Nordisk and Eli Lilly receive positive news amid ongoing developments in drug discovery and aging research.
◼ Archived
Business
Epic teams up with Amazon Pharmacy, Eli Lilly and Mark Cuban to launch prescription drug pricing tool
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
GLP-1 weight-loss drugs slow biological aging, recent studies show
Recent studies indicate that popular GLP-1 weight-loss medications like Ozempic and Mounjaro may also slow biological aging.
◼ Archived
Business
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.
◼ Archived
Business
‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
Lilly positions its retatrutide drug combo for a next-generation obesity battle following full phase 3 study results.
◼ Archived
Business
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Eli Lilly reports that its new combination obesity regimen, EloraTZP, outperformed tirzepatide in a mid-stage clinical trial.
◼ Archived
Business
Most powerful obesity drug yet: People lost up to 25% of weight in trial
Eli Lilly's experimental triple agonist drug retatrutide demonstrates significant weight loss and A1C reduction in recent clinical trials.
◼ Archived
Business
Experimental weight-loss shot helps patients keep weight off with fewer injections
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Novo Nordisk unveils its next growth engine at Capital Markets Day as competitor Eli Lilly gains ground in GLP-1s.
◼ Archived
Business
Eli Lilly CEO reveals astonishing shift in GLP-1 pill market
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
◼ Archived
Business
The company behind a new GLP-1 pill is betting $6.5 billion on Houston
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Eli Lilly is breaking ground in Houston on a facility planned for 2030
Eli Lilly plans a 2030 groundbreaking in Houston as weight-loss drug developers line up to tap a lucrative and increasingly competitive market.
◼ Archived
Health
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.
◼ Archived
Business
🔮 fades ✓
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
◼ Archived
Business
🔮 fades ✗
Cholesterol drug setback casts doubt over multibillion-dollar race
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.
◼ Archived
Business
🔮 fades ✓
Dairy company Chobani announces $1.2B investment in Pennsylvania
Chobani announces a $1.2 billion investment plan in Pennsylvania, boosting the Lehigh Valley economy according to recent coverage.
◼ Archived
Business
🔮 fades ✗
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion
Eli Lilly is expanding its autoimmune portfolio through the acquisition of Merida Biosciences in a deal valued at up to $2.875 billion.
◼ Archived
Business
🔮 fades ✓
Why some companies may not be offering coverage for GLP-1 weight loss drugs
Corporate insurance coverage for GLP-1 weight-loss drugs is declining as companies like PepsiCo remove these benefits to manage pharmacy costs.
◼ Archived
Business
🔮 fades ✗
Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.
Eli Lilly has introduced Foundayo, a new daily oral weight-loss medication, to the United Kingdom market, driving a significant rise in company stock.
◼ Archived
Business
🔮 fades ✗
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a first-of-its-kind blood test for Alzheimer's biomarkers developed through a partnership between Roche and Eli Lilly.
◼ Archived
Health
🔮 fades ✗
Researchers examine unanticipated benefits of GLP-1 medications
Researchers are investigating unexpected health benefits of GLP-1 medications as the drugs evolve beyond their primary use for weight loss.
◼ Archived
Business
🔮 fades ✓
Eli Lilly is suing six companies over illegal sales of its unapproved weight loss drug
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly targets the illicit market for its unapproved obesity drug retatrutide through new legal actions.
◼ Archived
Health
🔮 fades ✓
UK approves its second weight-loss pill while EU access lags
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
Lilly's weight-loss pill gets UK regulator's nod
The UK medicines regulator has approved a new once-daily weight-loss pill from Eli Lilly, offering an oral alternative to injectable GLP-1 treatments.
◼ Archived
Business
🔮 fades ✗
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Novo Nordisk’s once‑dominant GLP‑1 weight‑loss line now faces a fierce showdown with Eli Lilly, sparking questions about Europe’s biotech edge.
◼ Archived
Business
🔮 fades ✗
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Eli Lilly’s 48% revenue surge eclipses a weak earnings report from The Trade Desk, reshaping market expectations for biotech and ad tech alike.
◼ Archived
Business
🔮 fades ✓
Novo outlook hike falls flat as Wegovy pill sales fail to impress
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Options market braces for $225 billion swing in SpaceX's value as earnings loom
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Novo Nordisk shares slide after guidance disappoints investors
Novo Nordisk shares decline despite Q2 profit beats and raised forecasts, amid intensifying competition with Eli Lilly.
◼ Archived
Business
🔮 holds ✓
Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly
Eli Lilly has expanded its neuropsychiatric portfolio through a multi-billion dollar acquisition of Atai, a psychedelic research company.
◼ Archived
Business
🔮 fades
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
◼ Archived
Business
🔮 fades
Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle
Eli Lilly targets a first-quarter 2027 FDA application for its next-generation obesity drug retatrutide.
◼ Archived
Business
🔮 fades
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.
◼ Archived
Business
🔮 holds
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of deceptive and misleading advertising regarding GLP-1 weight-loss drugs.
◼ Archived
Business
🔮 fades
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has launched a legal offensive against Eli Lilly, alleging that the competitor's GLP-1 weight-loss drug advertising is deceptive.
◼ Archived
Business
🔮 fades
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
Eli Lilly's $3.8 billion acquisition of AtaiBeckley signals a major shift as Big Pharma begins to validate the psychedelic medicine sector.
◼ Archived
Health
🔮 fades
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?
FDA’s new peptide panel sparks regulatory debate as biotech giants Lilly and Novo eye the next health wave.
◼ Archived
Business
🔮 fades
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports
Eli Lilly is entering the psychedelic drug market with a deal to acquire AtaiBeckley for up to $3.8 billion to treat resistant depression.
◼ Archived
Business
🔮 fades
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics seeks $75 million in an IPO, testing market appetite for early-stage biotech.
◼ Archived
Business
🔮 fades
FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing
The FDA has launched the PreCheck pilot program with seven participants to accelerate and strengthen the domestic manufacturing of drugs in the United States.
◼ Archived
Business
🔮 fades
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
The European Medicines Agency has issued a positive opinion recommending the approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia.
◼ Archived
Health
🔮 fades
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Oral GLP-1 medications are gaining attention as clinical data emerges regarding their efficacy in weight management and potential to shift treatment paradigms.